Recruiting

Testing a clot-dissolving medication for stroke within 24 hours of onset

Plain-English translation of NCT07201688 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called (Mingfule), which is designed to dissolve blood clots in the brain during an acute stroke. The trial enrolls people who arrive at the hospital between 4.5 and 24 hours after stroke symptoms began. Half of the participants will receive the actual medication, and half will receive a placebo (a dummy treatment), so researchers can fairly compare whether the medication truly helps people recover better.

Standard stroke treatments work best only within the first few hours, leaving many stroke patients without options if they arrive later. This trial explores whether this medication can safely help people who present in the extended 4.5-to-24-hour window, potentially opening a new treatment opportunity for patients who would otherwise have very limited choices.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you arrive for treatment between 4.5 and 24 hours after your stroke symptoms started (including if you woke up with a stroke or the exact time is unknown)
you were living independently and in good health before your stroke (modified Rankin Scale score of 0–1)
you have a confirmed blood clot blocking a major artery in your brain (internal carotid artery or middle cerebral artery), confirmed by CT or MRI scan
your brain imaging shows the right pattern: a small area of permanent damage and a larger area of brain tissue that might still be saved

You likely don't qualify if…

you have a known allergy to the medication being tested
you have a bleeding disorder or take blood-thinning medications that cannot be managed safely
you have very low or very high blood sugar that cannot be controlled
you have active internal bleeding or a very high risk of serious bleeding
you have other serious medical conditions (such as severe uncontrolled high blood pressure, very low platelet count, or a seizure at the time of stroke) that would make the treatment unsafe

What participation looks like

If you join this study, you will be randomly assigned to receive either the new medication or a placebo injection while you are in the hospital being treated for your stroke. The study will follow you for about 90 days total, including the initial treatment period and follow-up visits to check how well you are recovering. Researchers will use brain scans, blood tests, and standard stroke recovery assessments to track your progress and compare outcomes between the medication group and the placebo group.

AI-generated summary from trial data · Jul 22, 2026 · Not medical advice

Testing a clot-dissolving medication for stroke within 24 hours of onset

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)